Foghorn Therapeutics, Inc. (FHTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.92+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FHTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.1% |
| Our one-year growth estimate | diamond | -8.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 26.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FHTX — earnings miss
Dated 2026-03-11
Results of Operations and Financial Condition. On March 11, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Why it matters: Watching cash burn helps check Foghorn's finances and its ability to fund programs.
Worry ifCash burn decreases below $25 million for the quarter.
Less concerning ifCash burn remains above $25 million or increases.
Why it matters: Good cash management is key for funding trials and operations. It shows financial health.
Watch forCash reserves remain stable or increase, extending the runway beyond H1 2028.
Also watch forCash reserves drop a lot or funding runs out sooner than expected.
Why it matters: Advancing clinical programs is a top priority. Delays could hurt growth potential.
Worry ifManagement starts a new clinical trial or shares good data.
Less concerning ifNo updates or further delays in clinical trials are reported.
Why it matters: Updates on the partnership show how Foghorn is doing in oncology and revenue.
Watch forNew milestones or good news in the partnership with Lilly.
Also watch forNo updates or bad news about the partnership.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $768 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,611 loss on $10,000 · 46.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The IND filing will indicate progress in developing a treatment for ER+ breast cancer. This could expand Foghorn's pipeline.
Supportive ifAnnouncement of the IND filing for FHT-171 expected in 2027.
Worry ifDelay in the IND filing or lack of progress reported on FHT-171.
Why it matters: Filing for EP300 degraders may provide more treatment options. This could help people with multiple myeloma and other cancers.
Supportive ifThe IND filing for Selective EP300 degraders was successful. They are aimed for 2027.
Worry ifDelay in filing for the IND beyond 2027 or failure to meet preclinical benchmarks.
Why it matters: Progress in the CBP degrader program may help treat ER+ breast cancer.
Supportive ifThere are positive updates on the CBP degrader program. It shows strong anti-tumor effects.
Worry ifThere are negative updates about the CBP degrader program. It shows poor results or delays.
Why it matters: Healthcare sector growth affects Foghorn's market. A rebound could boost sentiment.
Supportive ifHealthcare sector revenue growth speeds up to 9% or more.
Worry ifSector revenue growth slows down to below 9%.
Why it matters: Results will show if FHD-909 can effectively treat SMARCA4-mutant NSCLC. This is key for Foghorn's growth.
Supportive ifThe Phase 1 trial shows positive results. It confirms safety and effectiveness for patients with SMARCA4 mutations.
Worry ifNegative results show that it does not work well. There are no safety issues.
Why it matters: New data may show FHD-909 works well as a combination therapy. This could boost its market appeal.
Supportive ifNew preclinical data shows FHD-909 works better with anti-PD-1 therapy.
Worry ifLack of new data or negative results from combination studies.
Why it matters: Progress in this program may help treat multiple myeloma and other cancers.
Supportive ifThey shared good news about the EP300 degrader program studies.
Worry ifDelays or failures in studies may push back timelines.
Why it matters: Updates on cash management will show financial health. This affects funding for ongoing projects.
Watch forIncrease in cash reserves or positive cash flow from operations.
Also watch forA drop in cash reserves or negative cash flow shows financial strain.